We are live on ! Find out more
ADPT icon

Adaptive Biotechnologies

196 hedge funds and large institutions have $4.89B invested in Adaptive Biotechnologies in 2020 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 63 increasing their positions, 49 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

377% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 13

99% more call options, than puts

Call options by funds: $14.1M | Put options by funds: $7.06M

81% more capital invested

Capital invested by funds: $2.7B → $4.89B (+$2.19B)

33% more funds holding

Funds holding: 147196 (+49)

29% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 49

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

2.76% more ownership

Funds ownership: 76.87%79.63% (+2.8%)

Holders
196
Holders Change
+49
Holders Change %
+33.33%
% of All Funds
4.02%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.1%
New
62
Increased
63
Reduced
49
Closed
13
Calls
$14.1M
Puts
$7.06M
Net Calls
+$7.01M
Net Calls Change
+$7.78M

ADPT Hedge Fund Activity: Q2 2020 in Review

196 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2020, worth a combined $4.89B — up 81% from $2.7B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ADPT positions and 13 closed out — a net gain of 49 holders — while 63 added to existing stakes and 49 trimmed.

The largest buyer was Neuberger Berman Group, adding an estimated $44.7M. The largest seller was Wellington Management Group, cutting an estimated $100M.

  • 196 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2020, up from 147 in Q1 2020.
  • Funds reported $4.89B of Adaptive Biotechnologies stock for Q2 2020, up 81% quarter-over-quarter.
  • 62 funds opened new Adaptive Biotechnologies positions in Q2 2020 and 13 closed out, a net change of +49 holders.
  • The largest Adaptive Biotechnologies buyer in Q2 2020 was Neuberger Berman Group, an estimated $44.7M added.
  • The largest Adaptive Biotechnologies seller in Q2 2020 was Wellington Management Group, an estimated $100M sold.

Based on aggregated 13F filings for Q2 2020.